Join Hedi Ben Brahim, CEO of One Biosciences and a leading figure in the French biotechnology ecosystem, in an in-depth conversation with Gary Fowler as they explore how single-cell technologies are transforming precision medicine. Learn how One Biosciences is unlocking new therapeutic targets, expanding to the U.S., and navigating the challenges of scaling an innovation-driven biotech company.

Insights You’ll Learn:

✓ What single-cell analysis enables that traditional drug discovery cannot

✓ How One Biosciences identifies new targets for difficult-to-treat diseases

✓ Challenges and opportunities in expanding a European biotech to the U.S. market

✓ Why computational biology is central to the next wave of precision therapeutics

✓ How to build an integrated discovery engine combining wet lab and in- ...